Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$75.59 USD

75.59
1,583,946

+0.70 (0.93%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $75.60 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Zacks Equity Research

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?

by Zacks Equity Research

INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.

Zacks Equity Research

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

by Zacks Equity Research

Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.

Zacks Equity Research

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.

Zacks Equity Research

INCY vs. VRTX: Which Stock Is the Better Value Option?

by Zacks Equity Research

INCY vs. VRTX: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Zacks Equity Research

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. INCY: Which Stock Is the Better Value Option?

Zacks Equity Research

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

by Zacks Equity Research

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.

Zacks Equity Research

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More

by Zacks Equity Research

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals

by Zacks Equity Research

INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.

Zacks Equity Research

EXEL or INCY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. INCY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Zacks Equity Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Zacks Equity Research

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?

by Zacks Equity Research

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

by Zacks Equity Research

SAGE and INCY suffer setbacks due to the failure of HD and CSU studies, respectively.

Zacks Equity Research

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study

by Zacks Equity Research

INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.

Zacks Equity Research

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Zacks Equity Research

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

Zacks Equity Research

BMRN vs. INCY: Which Stock Is the Better Value Option?

by Zacks Equity Research

BMRN vs. INCY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Zacks Equity Research

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

by Zacks Equity Research

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.